Thought Leader Liaison

Overview

We are looking for an experienced Thought Leader Liaison to support the promotion of AMVUTTRA (vutrisiran). The Thought Leader Liaison (TLL) is a commercial, field-based, customer facing role primarily focused on the identification and development of enduring relationships with both current and emerging key opinion leaders (KOLs). S/he will focus on engaging KOLs to solicit insights and develop advocacy aligned to commercial and marketing strategy and messaging. As integral strategic partners to Alnylam‘s internal and field-based teams, TLLs support cross functional, commercial opportunities and engagements with KOLs including marketing education initiatives, advisory boards, speakers bureau strategy, congress strategy, and consulting opportunities. Additionally, the TLL helps to inform commercial and marketing strategy, messaging, and resources through the sharing of insights and connecting KOLs with Alnylam cross functional partners. The TLL role will work closely and collaboratively with internal partners including marketing, medical affairs, sales, legal, and compliance to maintain KOL coordination but also to manage appropriate distinction of roles and boundaries among the expertise areas.

Our team is at the forefront of commercializing an industry-leading TTR Franchise, with a focus on preparing for the potential launch of Vutrisiran in cardiomyopathy while continuing to establish market leadership for ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) in polyneuropathy. If approved, Vutisiran is anticipated to emerge with a market-leading profile in ATTR-CM, offering a unique mechanism of action and the potential for a highly impactful clinical profile in a rapidly growing market with significant unmet patient needs..

Key Responsibilities

• Creates and executes on objective-based, KOL engagement plans to include the identification and curation of relationships with current and emerging KOLs in the academic and community setting to support insight generation and development of advocacy in a dynamic market
• Assist Sr. Director, TLL Lead, with ongoing evaluation and creation of TLL strategy including focus, priorities, and tactical execution
• Solicits pre-determined disease and brand insights through field-based, 1v1 KOL interactions and utilizes these insights to identify market gaps and/or market opportunities to support the development of commercial and marketing strategy, initiatives, and resources
• Proactive collaboration with cross-functional field colleagues to ensure a One Alynlam approach to customer engagement
• Partners with cross functional colleagues to engage with professional societies and patient advocacy groups
• Engages in field-based, 1v1 interactions with KOLs using approved TLL resources to generate insights and align KOL beliefs to hATTR amyloidosis and AMVUTTRA (vutrisiran) disease and brand messaging to support advocacy development.
• Identify KOLs for approved Alnylam consulting engagements including the speaker‘s bureau, congress and regional symposiums, advisory boards, review of marketing materials, and KOL videos, etc.
• Support the execution of US marketing advisory boards including insights for creation of content and selection of advisors.
• Serve as a participant in cross functional, commercial planning and execution through leadership and support of quarterly business and account reviews
• Be an active contributor of TLL strategy, process, and congress identification by assisting the Sr Director team lead in the following:
• development of processes and tools to capture, assess, and communicate performance of TLL KOL engagement strategy
• Develop strategies for the acquisition of relevant market insights, interpretation of insights, and approved sharing of insights with internal stakeholders
• Support identification of opportunities for participation at congresses and regional conferences and develop and execute on the TLL strategy for these meetings
• Collaborate with legal, regulatory, and compliance stakeholders to ensure compliant development and execution of TLL strategy and tactics*Owns, develops, and executes on KOL engagement strategies for Alnylam‘s participation at key, national congresses within the hTTR amyloidosis community.
• Develops opportunities to communicate execution and commercial impact of the TLL role with internal partners and maintains proactive communication plans with cross functional partners to coordinate activity and ensure role clarity.
• Operates to the highest standard in alignment with Alnylam‘s code of ethics and compliance SOPs, ensuring all interactions with KOLs are on-label and consistent with commercial, regulatory, and legal guidelines.

Qualifications

Education: Bachelor‘s degree; sience degree preferred.

Experience:

• 8+ years of experience in one or more of the following: Field Sales, Product Marketing, and / or Medical Affairs within the pharmaceutical or biotech industry
• Experience and proven success in working with and interacting with HCPs (Healthcare Providers), KOLs (Key Opinion Leaders), and COEs (Centers of Excellence)
• Experience in high science areas of oncology or rare/orphan diseases desirable
• A track record of executing strategic and tactical plans that have delivered strong commercial results.
• Deep experience in Neurology and Cardiology is preferred.
• Proven ability to influence without authority and work with cross-functional teams in the development and delivery of brand strategic imperatives.
• Thrives in a highly entrepreneurial biotech environment and embraces Alnylam‘s culture of science, passion, and urgency.
• Maintains a growth mindset and uses curiosity to uncover opportunities for continuous development and improvement.
• Excellent interpersonal and communication skills.

Additional Requirements:

• Valid driver‘s license.
• Ability to travel approximately 60-70%, as necessary
• Must live within specified territory.

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by ‘interfering‘ with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we‘ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine‘s Top Biopharma Employers, one of America‘s Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.